Clinical trials: Myotonic Dystrophy 2
Myotonic Dystrophy Type 2
Clinical Outcome Measures in Myotonic Dystrophy Type 2
A monocentric, longitudinal, observational case-control study in patients with Myotonic Dystrophy type 2 (DM2). At least 60 DM2 will be evaluated through a battery of patients reported Outcomes (PROs) and clinical Outcome…
- Trial name
- COMEDY-2 (NCT03603171)
- Testing
- DM1-ActivC, R-PAct, Beck depression inventory
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Prof. Dr. Benedikt Schoser
Type 2 Diabetes Mellitus, Medical Education
Generative AI-Based Simulation for Diagnostic Communication in Type 2 Diabetes (DIALOGUE-DM2)
This randomized controlled trial evaluates the effectiveness of a generative artificial intelligence (AI)-based simulation program in improving diagnostic communication skills among medical students.
- Conditions
- Type 2 Diabetes Mellitus, Medical Education, Diagnostic Communication, Artificial Intelligence Simulation
- Trial name
- DIALOGUE-DM2 (NCT07252193)
- Testing
- AI-Based Simulation Training (DIALOGUE-DM2), Traditional Training
- Where
- Mexico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Weight Loss, Metabolic Syndrome
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes.
- Conditions
- Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity
- Trial name
- NCT05874635
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Myotonic Dystrophy Type 2, Myotonic Dystrophy Type 1
Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
Nearly two-third of patients with myotonic dystrophy type 2 (DM2) report that impaired cognition is among the most disabling symptoms and deeply affects their quality of life.
- Trial name
- BraCE-DM2 (NCT05854433)
- Testing
- Non-interventional study
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Healthy
BIOAVAILABILITY OF GLI/METXR (4/850 mg)
Objective: The purpose of this study is to evaluate the oral bioavailability of the combination Glimepiride/ extended release Metformin (GLI/METXR) (4/850mg) in healthy Mexican volunteers in fasting conditions.
- Trial name
- GLMT12-SIL (NCT01437800)
- Testing
- Glimepiride / Extended release Metformin (4/850 mg).
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1)
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
The primary aim is to characterize the prevalence, severity and quality of musculoskeletal nociceptive pain in adult patients with neuromuscular disorders (NMD).
- Conditions
- Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2, Spinal Muscular Atrophy Type 3
- Trial name
- NCT04907162
- Testing
- Beck depression inventory fast screen, German Pain Inventory, Brief Pain Inventory
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- LMU Klinikum
Glycogen Storage Disease Type 2, Dystrophia Myotonica
An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica-
The aim of the project is to develop new Magnetic Resonance (MR) imaging techniques for better diagnosis and monitoring of patients with muscular disorders.
- Trial name
- NCT02708784
- Where
- 2 sites in Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Myotonic Dystrophy 1, Myotonic Dystrophy 2
Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study
The natural history of brain affection in myotonic dystrophy types 1 and 2 is still unknown. The investigators designed a 5-year longitudinal neuropsychological and neuroimaging follow-up study to address this issue.
- Trial name
- NCT02729597
- Testing
- medical history, neurological clinical examination, neuropsychological testing
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Dysautonomia
Autonomic Cardiovascular Neuropathy in Recently Diagnosed DM2 Patients (ACNDM2)
The investigators are studying the initial autonomic alterations in participants recently diagnosed with DM2 and in those patients classified as Pre-Diabetes, mainly focused on the baroreceptor sensitivity and on the peripheral…
- Trial name
- ACNDM2 (NCT02931773)
- Testing
- Task Force® Monitor
- Where
- Mexico
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Non Invasive Prenatal Diagnosis
NIPD on CFTC for Triplet Repeat Diseases
The purpose of this study is to develop and validate an analytical and clinical NIPD test for triplet repeat diseases by isolated circulating fetal trophoblastic cells (CFTC) analysis from maternal blood, searching for the…
- Trial name
- DIACCIMEX (NCT03087526)
- Testing
- Non invasive prenatal diagnosis
- Where
- 8 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Severe Obesity, Type 2 Diabetes Mellitus in Obese
L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP
Prevalence of Obesity and its association with Diabetes Mellitus 2 (DM2) affect a significant percentage of the world's population with great socioeconomic impact, especially for developing countries.
- Trial name
- NCT05446415
- Testing
- Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue.
- Conditions
- Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, Muscular Dystrophy, Myotonic Dystrophy Type 1
- Trial name
- NCT00082108
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Diabetes Mellitus, Type 2
Comparative Effectiveness of POC-A1c vs the Current Standard Based on OGTT for Early Detection DM2 in Colombia
Evaluate the impact of conducting a screening questionnaire (FINDRISC) and the implementation of a point-of-care HBA1c test for those with identified risk to suffer Diabetes in ten years, to improve the proportion of patients…
- Trial name
- EDDIT-1 (NCT05440968)
- Testing
- Point of Care - Glycated Hemoglobin (A1c), Oral Glucose Tolerance Test
- Where
- Colombia
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Humberto Reynales MD MSc PhD
Obstructive Sleep Apnea, Diabetes Mellitus
Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea
The investigators plan to recruit 140 patients (35 subjects in each group) over a period of 18 months in a prospective study of matched/paired case-control subjects across the four groups to measure the 5-year risk of developing…
- Trial name
- OSA & DM (NCT01447251)
- Testing
- PreDx Diabetes Risk Score
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Mike O'Callaghan Military Hospital
Diabetes, Malnutrition
Study About Adherence and Tolerance of an Oral Nutritional Supplement (ONS) Specific for Diabetic Patient.
Diabetes Mellitus (DM) is one of the most prevalent chronic diseases today, it is reaching epidemic proportions, mainly caused by the increase in type 2 diabetes (DM2).The foundation of any hypoglycemic treatment is based on a…
- Trial name
- DIABEST (NCT05488210)
- Testing
- FontActiv DiaBest HP/HC
- Where
- Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Impaired Blood Glucose Level, Overweight
Early Diagnosis of Diabetes Mellitus Type 2 (DM2)
Rationale: The global prevalence of diabetes, along with its devastating effects on life expectancy and quality of life, continues to increase.
- Conditions
- Impaired Blood Glucose Level, Overweight, Obesity
- Trial name
- 7348 (NCT00469287)
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- TNO
Healthy
BIOAVAILABILITY OF Glimepiride/Extended Release Metformin (GLI/METXR): High Fat Diet Study
Objective: The purpose of this study is to evaluate the effect of food intake in bioavailability (BA) of the combination Glimepiride/ extended release Metformin GLI/METXR (4/850mg) in healthy Mexican volunteers.
- Trial name
- GLMT13 (NCT01437813)
- Testing
- Glimepiride/ Extended release Metformin
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.